Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASH 2015 - Multiple Myeloma
Bortezomib/Melphalan/Prednisolone Induction Therapy Followed by Lenalidomide/Dexamethasone Consolidation and Lenalidomide Maintenance in Transplant-Ineligible Patients with Newly Diagnosed MM
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
The Relevance of Minimal Residual Disease Monitoring in Elderly Multiple Myeloma Patients
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Patient Preferences on Treatment Attributes in MM
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Management of Infusion-Related Reactions Associated with Daratumumab Monotherapy in RRMM
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Final OS Analysis of Panorama 1 Trial of Panobinostat/Bortezomib/Dexamethasone in RRMM
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Lenalidomide/Dexamethasone versus Bortezomib/Lenalidomide/Dexamethasone in Newly Diagnosed Multiple Myeloma: Results of the Phase 3 SWOG S0777 Trial
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Randomized Phase 2 Study of the All-Oral Combination of Ixazomib plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
ELOQUENT-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma—3-Year Safety and Efficacy Follow-Up
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-Up of the HOVON-65/GMMG-HD4 Trial
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma